BioArctic

BioArctic Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of BioArctic (BIOA B.ST) as of Nov 9, 2026 is 139.98 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 178.64 % — a change of -21.64% (lower).

Cash Conversion

139.98 %

YoY

-21.64%

Last updated:

Cash Conversion Rate (OCF/Net Income) of BioArctic is 2025 139.98 % . Cash Conversion Rate (OCF/Net Income) of BioArctic was 2024 178.64 % . It decreases by -21.64% lower compared to the previous year.

The BioArctic Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
-52.43 SEK
Jan 1, 2019
369.81 SEK
Jan 1, 2020
134.77 SEK
Jan 1, 2021
117.25 SEK
Jan 1, 2022
283.04 SEK
Jan 1, 2023
135.09 SEK
Jan 1, 2024
178.64 SEK
Jan 1, 2025
139.98 SEK
The BioArctic Cash Conversion history
YEARCash ConversionYoY
139.98 %-21.64%
178.64 %+32.24%
135.09 %-52.27%
283.04 %+141.39%
117.25 %-13.00%
134.77 %-63.56%
369.81 %-805.41%
-52.43 %-94.13%
-892.83 %-176.15%
1,172.51 %-364.70%
-442.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Cash Conversion Rate (OCF/Net Income) of BioArctic is 139.98 % in 2025.

Cash Conversion Rate (OCF/Net Income) of BioArctic changed from 178.64 % to 139.98 %, representing a -21.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) BioArctic since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioArctic

All Key Metrics — BioArctic